注册 | 登录
点击这里给我发消息
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   基因重组   >   Anti-IFNg Reference Antibody (fontolizumab)   

Anti-IFNg Reference Antibody (fontolizumab)

Recombinant Antibody

     
  • 0 - Anti-IFNg Reference Antibody (fontolizumab) APR10220
    Anti-IFNg Reference Antibody (fontolizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%
  • 0 - Anti-IFNg Reference Antibody (fontolizumab) APR10220
    The purity of Anti-IFNg Reference Antibody (fontolizumab)is more than 95% ,determined by SEC-HPLC.
  • 0 - Anti-IFNg Reference Antibody (fontolizumab) APR10220
    Immobilized human IFN γ His at 2  µg/mL can bind Anti-IFNg Reference Antibody (fontolizumab),EC50=0.007326 µg/mL
  • 产品详情
  • 实验流程
Product Information
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
FC, Kinetics, Animal Model
Primary Accession P01579
Reactivity Human
Clonality Monoclonal
Isotype IgG1
Calculated MW 19348 Da
Additional Information
Target/Specificity IFNg
Endotoxin < 0.001EU/ µg,determined by LAL method.
Conjugation Unconjugated
Expression system CHO Cell
Format Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.
Protein Information
Name IFNG
Function Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation (PubMed:16914093, PubMed:8666937). Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation (PubMed:8349687). Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription (PubMed:16914093). Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits (PubMed:8666937). In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading (PubMed:8163024). Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference (PubMed:11112687). Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL (PubMed:7729559). Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation (By similarity).
Cellular Location Secreted.
Tissue Location Released primarily from activated T lymphocytes.
Research Areas

For Research Use Only. Not For Use In Diagnostic Procedures.

FeedBack

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-88856768 tech-china@abcepta.com.


我要评价